Name: Latest research reports of Laurus Labs Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

790.2000 -3.30 (-0.42%)

NSE Jul 11, 2025 15:31 PM

New 52W High in past week

Volume: 1.5M

Laurus Labs Ltd.

27 Jan 2025

790.20

-0.42%

Laurus Labs (SELL): Margin guidance shifted from 20% to closer to 20% for FY25E

Sell: Laurus Labs Ltd.

Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 10.5%/46.6%/227%. EBITDA margin surpassed our estimate by 500bps

Laurus Labs Ltd. has gained 30.43% in the last 3 Months